MedTrace Logo

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

NCT06245629 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-11-29

No results posted yet for this study

Summary

This project will evaluate the efficacy and safety of the conditioning regimen bortezomib-bendamustine-melphalan (BBM) in combination with autologous hematopoietic stem cell transplantation (ASCT) in relapsed multiple myeloma given from 2011 to 2018 at Uppsala University Hospital. This approach will be retrospectively compared to high dose melphalan (HDM) in the same setting in the years prior to, and following the BBM-period. Data on efficacy and safety data will be collected through systematic analysis of electronic medical records and from the Swedish Cancer Registry.

Conditions

  • Myeloma Multiple

Interventions

DRUG

Bortezomib-bendamustine-melphalan

The aim of this retrospective cohort study is to evaluate the efficacy and safety of the conditioning regimen BBM compared to HDM in the setting of relapsed multiple myeloma.

Sponsors & Collaborators

  • Uppsala County Council, Sweden

    collaborator OTHER_GOV

  • Dalarna County Council, Sweden

    collaborator OTHER

  • Uppsala University

    lead OTHER

Principal Investigators

  • Honar Cherif, MD, PhD · Uppsala University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-24
Primary Completion
2025-03-31
Completion
2025-11-30
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06245629 on ClinicalTrials.gov